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Abstract
Background: Acid sphingomyelinase (ASM) hydrolyses sphingomyelin and generates the lipid messenger ceramide, which
mediates a variety of stress-related cellular processes. The pathological effects of dysregulated ASM activity are evident in
several human diseases and indicate an important functional role for ASM regulation. We investigated alternative splicing as
a possible mechanism for regulating cellular ASM activity.
Methodology/Principal Findings: We identified three novel ASM splice variants in human cells, termed ASM-5, -6 and -7,
which lack portions of the catalytic- and/or carboxy-terminal domains in comparison to full-length ASM-1. Differential
expression patterns in primary blood cells indicated that ASM splicing might be subject to regulatory processes. The newly
identified ASM splice variants were catalytically inactive in biochemical in vitro assays, but they decreased the relative
cellular ceramide content in overexpression studies and exerted a dominant-negative effect on ASM activity in physiological
cell models.
Conclusions/Significance: These findings indicate that alternative splicing of ASM is of functional significance for the
cellular stress response, possibly representing a mechanism for maintaining constant levels of cellular ASM enzyme activity.
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Introduction
Acid sphingomyelinase (ASM, EC 3.1.4.12) is a glycoprotein
localised primarily to the lysosome where it catalyses the
breakdown of sphingomyelin to ceramide and phosphorylcholine
at a pH optimum of 5 [1]. On the one hand, ASM activity changes
the lipid composition of membranes. On the other, ASM
generates the bioactive lipid ceramide. According to the ‘rheostat
concept’ [2], increased ceramide levels promote apoptosis,
whereas an increase in the phosphorylated metabolite of ceramide,
sphingosine-1-phosphate, counteracts this effect by inducing
proliferation [3]. The dynamic balance between these bioactive
lipids is influenced by the activities of acid ceramidase, sphingosine
kinase, sphingosine-1-phosphate phosphatase, sphingosine-acetyl-
transferase and ASM. Among these enzymes, ASM holds a
prominent position because it generates the first bioactive
molecule in the rheostat. Consequently, abnormal ASM activity
is linked to different pathological conditions. Dramatically
decreased ASM activity, due to inherited sequence variations in
the SMPD1 gene coding for ASM, is the cause of the type A and B
forms of Niemann-Pick disease [4]. Elevated ASM activity is
associated with different neuro-psychiatric disorders like Alzhei-
mer’s dementia [5], status epilepticus [6], alcoholism [7] and
major depression disorder [8]. Due to these pathological
consequences, the tight regulation of ASM activity is crucial for
normal cellular function.
A variety of external stress stimuli leads to the activation of
ASM, such as CD95 ligand [9], lipopolysaccharide [10], ionising
radiation [11], cisplatin [12] and tumour necrosis factor-a [13] to
name a few. Different stimuli lead to an upregulation of ASM at
the transcriptional level [14,15,16,17,18], representing a slow
regulatory response. In contrast, post-translational modifications
act as a fast regulatory response to external stimuli. In vitro
activation of ASM results from interaction with zinc [19] and
copper ions. The latter mediates ASM dimerisation via a cysteine
(at position p.631) at the carboxy (C)-terminus of the protein [20].
An activating effect is also exerted by protein kinase d, which
phosphorylates a serine residue (at position p.510) located in the
C-terminal domain of ASM [21].
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although only one has been reported to be catalytically active.
Consequently, ASM regulation may also involve alternative
splicing. Thus far, only the full-length transcript (GenBank
Accession Number NM_000543.4; referred to as ASM-1 in this
manuscript) has been shown to code for an active enzyme. This
transcript is composed of exons 1 to 6 with a total coding length of
1896 bp. Relative to ASM-1, the alternatively spliced transcript
ASM type 2 (NM_ 001007593.1; termed ASM-2) contains a 40 bp
insertion derived from intron 2 and lacks exon 3. The alternatively
spliced transcript ASM type 3 (NR_027400; termed ASM-3) lacks
exon 3. This creates a frameshift in the coding sequence and leads
to premature termination during translation [22,23]. An addition-
al ASM transcript, which lacks 652 bp of exon 2, was isolated from
human brain tissue (AY649987.1; referred to as ASM-4).
In this study, we identified three hitherto unknown alternatively
spliced human ASM transcripts, which we termed ASM-5, ASM-6
and ASM-7. The characterisation of intrinsic biochemical
properties indicated that none of the newly identified ASM
variants is catalytically active in vitro. However, the new variants
exert a dominant-negative effect on cellular ceramide content and
on ASM activity. This study provides the first evidence of a
regulatory effect of alternatively spliced ASM transcripts.
Results
Identification of New ASM Splice Variants in Human Cells
Because a variety of orthologous transcripts has been described
for ASM in public databases, we investigated the human ASM
transcriptome more closely. In a first screen on human
neuroglioma cells and PBMCs, 24% of the 17 analysed ASM
transcripts had undergone alternative splicing. We identified three
ASM transcripts from human cells that have not been described
before. Following the convention of the already present human
ASM transcripts in GenBank, the new transcripts were termed
ASM-5 (GenBank Accession Number HQ132746), ASM-6
(HQ132747) and ASM-7 (HQ132748) (Figure 1).
ASM-5 was isolated from human neuroglioma cells. It lacks the
first 69 bp of exon 3 (relative to ASM-1), which results in a
reduced transcript length of 1818 bp (Figure S1). At the protein
level, the deletion disrupts the catalytic domain of the putative
enzyme (606 aa; theoretical molecular weight of 67 kDa) as amino
acids 362 to 384 are absent from the protein (Figure S2). ASM-6,
identified in human neuroglioma cells, is characterised by a 20 bp
intronic insertion derived from the end of intron 5 proximal to
exon 6 (exon 5a). This generates a transcript of 1907 bp. The
intronic insertion creates a frameshift in the coding sequence. The
frameshift introduces a premature stop codon (TAG) and results in
a truncated open reading frame of 1521 bp (Figure S1).
Consequently, the putative protein (506 aa; theoretical molecular
weight of 56 kDa) displays only a partial C-terminal domain in
which the terminal 136 amino acids of ASM-1 have been lost and
replaced by a unique peptide of 13 amino acids
(VSPTSLQVTVCTK) (Figure S2). ASM-7 was identified in
human PBMCs and contains a 40 bp intronic sequence derived
from the beginning of intron 2 proximal to exon 2 (exon 2a). The
resulting transcript is 1921 bp in length. This intronic insertion
creates a frameshift and a premature stop codon (TGA), resulting
in an open reading frame of 1197 bp (Figure S1). The putative
enzyme (398 aa; theoretical molecular weight of 45 kDa) displays
only a fragment of the catalytic domain and is devoid of its
carboxy-terminal domain because it lacks the C-terminal 267
amino acids. In its place, it carries a unique carboxy-terminal
peptide of 38 amino acids (YLSSVETQEGKRKNWGVL-
CSFPIPRSPPHLSQYEFLFP) (Figure S2). For an overview see
Table 1.
An in silico examination of conservation among orthologues
revealed that ASM-6 displays the same combination of splicing
events as orthologous ASM transcripts from Pan troglodytes
(XM_001164317.1) and Macaca mulatta (XM_001110020.1).
ASM-7 exhibits a combination of splicing events identical to that
of the orthologous ASM transcript expressed in Pongo abelii
(NM_001132129.1). No orthologous transcript contained the type
of splicing event identified in ASM-5 (Table 1).
In a second screen on human brain tissue, 28% of the 149
analysed ASM transcripts had undergone alternative splicing.
These data confirm the high frequency of alternative splicing seen
in our first screen results. The splicing events that occur in ASM
Figure 1. A schematic of the genomic alignment of full-length ASM-1 and all known splice variants. ASM-1 constitutes the reference
sequence to which all other ASM variants are compared. The novel variant ASM-5 lacks part of exon 3, resulting in a shorter (1818 bp) coding
sequence. Novel variants ASM-6 and ASM-7 contain different intronic insertions. Consequently, their transcript lengths are 1907 bp and 1921 bp,
respectively. The insertions create frameshifts in the coding sequence and introduce premature stop codons, which terminate translation after
1521 bp and 1197 bp, respectively. For information on the previously described variants ASM-2, -3, -4 see [22,23]. In this schematic, lines represent
genomic sequences, black boxes indicate exons translated as in ASM-1, grey boxes refer to exonic sequences translated into different amino acids
due to a frameshift or coding sequences that correspond to introns in ASM-1, and white boxes denote exonic sequences that follow a premature
termination codon.
doi:10.1371/journal.pone.0035467.g001
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and, thus, may constitute the whole ASM transcriptome.
Thus, ASM is subject to alternative splicing processes, which
generate distinct transcripts through a defined set of splicing
events. These splicing events are likely to be highly conserved.
ASM Splicing Patterns Vary in Human Tissues
To explore the tissue-specific expression of ASM splice variants,
we analysed all splicing events in the splicing-relevant parts of
ASM using fluorescence-based quantification of electrophoretical-
ly separated RT-PCR products. ASM isoform ratios were
determined for 16 different human tissues and comprised all
splicing events between exons 2 and 4 and exons 4 and 6. Isoform
fractions derived from splicing events between exons 2 and 4
varied between 11% and 14%, showing a low level of variation
between tissues. Of note, four tissues were found to express much
higher levels of alternatively spliced transcripts: the brain (29% of
total ASM transcripts), the small intestine (21%), the placenta
(18%) and the prostate (17%). Isoform fractions between exons 4
and 6 accounted for 10–12% of all ASM transcripts, showing low
levels of variation (CV of 7%) (Figure 2A). Thus, ASM alternative
splicing varies by tissue, with more variation in splicing events
between exons 2 and 4.
For the determination of inter-individual variation in ASM
alternative splicing, we investigated the RNA of human lympho-
blastoid cell lines, which were derived from human donors.
Isoform fractions showed a low level of inter-individual variation
in splicing events occurring between both exons 2 and 4 (14–17%
of total ASM transcripts, CV of 11%) and exons 4 and 6 (9–13%,
CV of 9%) (Figure 2B). ASM alternative splicing therefore seems
to be constant in human B-lymphocyte cell lines.
To test the inter-individual variation of ASM splicing in human
primary cells, we conducted an analysis on whole-blood RNA
from 22 healthy donors. Surprisingly, the relative contribution of
ASM isoforms to the total number of ASM transcripts varied
highly between subjects (10–99%, CV of 44%) (Figure 2C). This
high level of variation between subjects was also observed during
an analysis of these RNA samples using RT-qPCR for variants
ASM-1 and ASM-5 to -7 (Data not shown). ASM alternative
splicing in primary blood cells is highly different between
individuals and thus seems to be context-dependent and under
some regulatory control.
New ASM Splice Variants are Catalytically Inactive
To analyse the intrinsic biochemical properties of ASM splice
variants resulting from typical splicing events in more detail, the
respective cDNAs were cloned into expression vectors. Western
blot analyses showed that ASM-1 and each of the new splice
variants ASM-5 to -7 were translated into protein upon
overexpression and displayed the predicted sizes (Figure 3A).
An in vitro enzymatic assay using radiolabelled C12-sphingomy-
elin as substrate [24] revealed that ASM-1 overexpression in H4
cells significantly increased ASM activity in cell lysates by 9-fold
over endogenous levels (63.4622.5 pmol/h/mg (overexpressed
ASM activity) versus 8.165.5 pmol/h/mg (endogenous ASM
activity); p,0.001; n=8). In contrast to ASM-1, none of the
alternatively spliced variants displayed catalytic activity that was
above endogenous levels (Figure 3B), despite easily detectable
expression of each of the proteins. To assess the impact of the C-
terminal tag, we expressed variants without the FLAG-tag, but this
did not alter the results. Similar results were obtained when the
experiments were repeated with HeLa and HEK293 cell lines,
varying cell numbers, five different plasmid preparations and
expression constructs with a different epitope tag. The results were
confirmed by an alternative ASM activity assay involving a
fluorescent C12-sphingomyelin substrate and thin layer chroma-
tography (Data not shown).
We concluded that the new ASM isoforms are catalytically
inactive, irrespective of whether they retain the catalytic domain or
not.
New ASM Splice Variants Act in a Dominant-negative
Manner upon Overexpression
Based on the intrinsic properties of the new ASM isoforms, their
role for sphingolipid metabolism in vivo was more specifically
defined. We examined to what extent the new ASM isoforms
modulate the physiological occurring ceramide and sphingomyelin
species levels (Table S1) using MALDI-TOF MS analysis.
Overexpression of ASM-1 significantly increased the ratio of
ceramide to sphingomyelin in H4 cells by 1.8-fold compared to the
control (p,0.01; n=3). This is consistent with the assumption that
increased ASM activity results in increased conversion of
sphingomyelin to ceramide. In contrast, transfection of the new
ASM splice variants had the opposite effect. The ceramide to
sphingomyelin ratio decreased to 26–38% of the control (p,0.01
for ASM-6; p,0.05 for ASM-5 and -7) (Figure 4A). Thus, the
novel ASM splice variants appear to exert an inhibitory effect on
cellular sphingomyelin hydrolysis in vivo.
The modifying impact of the novel ASM splice variants on
ASM activity was further investigated in co-transfection experi-
ments, where the novel human and non-conserved splice variant
ASM-5 was co-transfected with ASM-1. Western blotting
indicated that both ASM-5 and ASM-1 were expressed
(Figure 4B). Expression of ASM-1 alone caused a significant
increase in ASM activity over endogenous levels (p,0.001; n=6),
whereas expression of ASM-5 alone did not result in increased
ASM activity. Of note, co-transfection of ASM-5 with ASM-1
significantly reduced ASM activity compared to ASM-1 overex-
pression alone (9-fold vs. 17-fold over endogenous levels; p,0.01)
Table 1. Characteristics of the newly identified ASM splice variants.
ASM variant Accession No. Alternative splicing event Affected exon Orthologous transcripts Impact on protein structure
ASM-5 HQ132746 Acceptor downstream of exon 2 Exon 3 - Disruption of catalytic domain
ASM-6 HQ132747 Intron between exon 5 and 6 Exon 6 Pan troglodytes Disruption of C-terminal domain;
Macaca mulatta Specific peptide
ASM-7 HQ132748 Intron between exon 2 and 3 Exon 2 Pongo abelii Disruption of catalytic and
C-terminal domain; Specific peptide
Exon numbers are based on the full-length ASM-1 transcript.
doi:10.1371/journal.pone.0035467.t001
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ASM-1 activity.
Physiological Cell Models Confirm the Dominant-
negative Effect of New ASM Splice Variants
To determine the biological relevance of alternatively spliced
ASM, we investigated the dominant-negative effect in physiolog-
ical cell models. THP-1 cells treated with the phorbol ester PMA
serve as a well-established model for monocyte differentiation.
During monocyte to macrophage differentiation, transcription of
ASM is upregulated [15]. THP-1 cells were treated with PMA and
analysed at different time points. Expression levels of each novel
splice variant were analysed using quantitative RT-PCR and
correlated with the respective cellular ASM activity levels. Upon
PMA treatment, ASM-1 mRNA expression was time-dependently
induced, which cumulated in 36-fold expression after 48 h.
However, elevated ASM-1 mRNA expression was accompanied
by a disproportionately strong increase in the mRNA of the novel
ASM splice variants (up to 200-fold) (Figure 5A). Of note, despite
the clear increase in ASM-1 mRNA, ASM activity levels remained
unchanged upon PMA treatment (Figure 5B). This is consistent
with the assumption that an increased expression of ASM isoforms
prevents an increase in ASM activity. Thus, the dominant-
negative effect exerted by novel ASM splice variants may play an
important role during monocyte to macrophage differentiation.
A further physiological cell model deals with the well-known
phenomenon that sphingolipid metabolism significantly differs
depending on cell confluence levels [25]. H4 cells were grown to
varying levels of confluence and analysed for expression levels of
each novel splice variant and their respective cellular ASM activity
levels. ASM-1 mRNA expression was low in preconfluent H4 cells,
but significantly increased when cells became confluent or over-
confluent (4-fold; p,0.001; n=3). In contrast, expression of new
splice variants ASM-5, -6 and -7 rose 2-fold at most (Figure 5C).
As ASM-1 mRNA expression significantly increased at cellular
confluence, so did ASM activity levels (2.7-fold; p,0.001; n=3)
(Figure 5D). In this model, the novel splice variants were not
significantly induced. Analogously, the confluence-mediated
increase in ASM-1 mRNA expression resulted in a significantly
increased ASM activity level. This indirectly stresses the influence
of ASM splice variants on cellular ASM activity.
Discussion
In this study, we identified three new alternatively spliced
human ASM transcripts. Contrary to the previously described
finding that ASM-1 constitutes 90% of the ASM transcripts and
alternatively spliced variants 10% [22,23], we detected a much
higher frequency of alternative splicing events for ASM in our
screens. This difference in splicing frequencies may be due to the
different tissues under investigation. Former studies analysed
cDNA libraries of fibroblast, placental and testis tissue, while our
study screened neuronal cells and blood cells. In our quantitative
Figure 2. Extent of tissue-specific ASM isoform expression. A.
Human tissues. ASM isoform expression varied tissue-specifically,
depending on the type of splicing event. Isoform fractions derived from
splicing events between exons 2 and 4 showed high levels of variation,
with brain tissue expressing the highest percentage of ASM isoforms.
Isoform fractions derived from splicing events between exons 4 and 6
showed low levels of variation. Capillary electrophoresis with laser-
induced fluorescence analysis was conducted on triplicate RNA
isolations of different human tissues. Data indicate ASM isoform
percent fractions of splicing events occurring between exons 2 and 4
and exons 4 and 6. B. Human lymphoblastoid cell lines. ASM
isoform expression in human lymphoblastoid cell lines revealed a low
level of inter-individual variation for splicing events occurring between
exons 2 and 4 and exons 4 and 6. Capillary electrophoresis with laser-
induced fluorescence analysis was conducted on triplicate RNA
isolations. Data indicate ASM isoform percent fractions of splicing
events occurring between exons 2 and 4 and exons 4 and 6. C. Human
primary blood cells. ASM isoforms were expressed in each of the 22
healthy individuals’ blood cell RNA, but the relative contribution of ASM
isoforms to the total amount of ASM transcripts varied highly between
subjects. Capillary electrophoresis with laser-induced fluorescence
analysis was conducted. Data indicate ASM isoform percent fractions
of splicing events occurring between exons 2 and 6.
doi:10.1371/journal.pone.0035467.g002
Function of Acid Sphingomyelinase Splice Variants
PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e35467analysis of further tissues we found that there exist five tissues,
which constitute an exception to the 10% alternative splicing level:
the brain, the small intestine, the placenta, the prostate and blood
cells. It should be noted that alternative splicing is particularly
important for neuronal functions [26] and that the brain exhibits
the highest number of tissue-specific splice variants [27]. This is in
line with our analysis of tissue-specific ASM splicing because brain
tissue comprised 30% of alternatively spliced ASM variants.
A second important point is the considerable influence of
external stimuli such as cellular stress on splice site selection [28].
Importantly, the main features of the mammalian stress response
include changes in the peripheral and central nervous systems and
modifications to blood cell composition. For example, stress-
induced alternative splicing of the acetylcholinesterase enzyme
occurs selectively in brain and blood cells [29]. The alternative
splicing of ASM may be analogous: tissue dependent and
particularly abundant in brain and blood cells as part of the
cellular stress response. This hypothesis is reinforced by our results
regarding the splicing patterns in human primary blood cells and
in the monocyte cell line THP-1. In both cases, the variation levels
of ASM splicing are very high. In the THP-1 model, alternative
splicing varies depending on external stimulation by PMA, which
in turn has influence on ASM activity. Since ASM activity in blood
cells fluctuates and is influenced by diverse factors, also alternative
splicing in blood cells could be influenced, explaining the high
inter-individual differences. Due to the constant splicing levels in
B-lymphoblasts in our experiments and the importance of ASM
for macrophage biology [30], it seems likely that the varying
splicing patterns in primary blood cells result selectively from
macrophages and are triggered by the specific physiological
context. In future studies, splicing patterns for separated blood cell
populations should be monitored.
Because ASM plays an essential role in the fragile balance of the
rheostat, ASM alternative splicing is expected to occur within a
highly regulated context. There seems to be only a limited number
of splicing events that generate the alternatively spliced ASM
transcripts. These splicing events and even their specific
combinations are conserved among different species. For example,
the 40 bp intronic sequence from intron 2 found in ASM-7 is
identical to a splicing event in ASM-2 and to certain orthologues
in other species. Similarly, the 20 bp intronic sequence from
intron 5 in ASM-6 is the same as one of the events in transcript
ASM-4 and its orthologues. The splicing event that generates
transcript ASM-5 seems to be unique for humans thus far; there
are no equivalent motifs present in ASM transcripts from other
species. It is under discussion that the brain-related diversification
between primates and humans occurred as a result of an increase
in alternative splicing [31,32]. In this context, ASM-5 might
contribute specifically to the regulation of the human stress
response.
The modification of protein properties as a result of alternative
splicing, such as an alteration to the intrinsic catalytic property of
an enzyme, is a well-documented phenomenon [33,34,35]. A
switch from enzymatic activity to inactivity can be triggered by
stress signals via the mechanism of alternative splicing [28]. Full-
length ASM-1 consists of a regulatory saposin-B domain, a
catalytic domain and a C-terminal domain. The C-terminal
domain is thought to mediate ASM dimerisation [20]. The
proteins generated by the alternative splicing of ASM that have
been studied so far are catalytically inactive. Not all, however, are
characterised by a disrupted catalytic domain. For ASM-6, the
disruption of the C-terminal domain generates a catalytically-
inactive ASM isoform. Thus, it would appear that the C-terminal
domain plays an essential role in ASM function. This is supported
by analyses of SNPs associated with Niemann-Pick disease type A
and B. The SNPs that cause the loss of ASM function are located
within the coding sequences for the catalytic but also for the C-
terminal domain [36,37,38,39,40,41,42,43,44]. The dominant-
negative isoform ASM-5 retains all domains present in ASM-1
except a small portion of the catalytic domain. Thus, the
dominant-negative effect could be mediated via the dimerisation
of ASM-1 with ASM-5 which seems to be augmented in serum-
starving conditions. The dominant-negative mode of action of
ASM-5 may be an important step in preventing an induced
activation of ASM-1, which would otherwise lead to ceramide
accumulation and ceramide-induced responses. These processes
could help to regulate cellular homeostasis. A good example of a
physiological role for this effect is given by our THP-1
experiments. Despite clearly elevated ASM-1 mRNA levels during
differentiation (see also [15]), ASM activity levels remained
Figure 3. Biochemical characterisation of ASM-1 and the novel isoforms ASM-5, -6 and -7. A. Expression of ASM-FLAG constructs in
HeLa cells. ASM-1 and ASM-5 to -7 produced proteins that corresponded to their predicted sizes. Lysates were analysed by Western blotting 48 h
after transfection. ASM-FLAG variants were detected using an anti-FLAG antibody. The cloning vector served as a negative control; GAPDH was used
as a loading control. M indicates the size marker. B. Novel variants ASM-5 to -7 are catalytically inactive. ASM-1 overexpression significantly
increased ASM activity relative to the vector control (p,0.001), in sharp contrast to the novel isoforms ASM-5, -6 and -7. Lysates were subjected to an
in vitro enzyme activity assay 48 h after transfection of H4 cells with 7.5 mg of the respective ASM-FLAG construct. The results are provided as the fold
increase in ASM activity relative to the control (set to 1). Bars indicate mean values of n=8 independent experiments; error bars indicate SD. Statistical
significance was calculated with respect to the control using a one-sampled t-test (***p,0.001).
doi:10.1371/journal.pone.0035467.g003
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mRNA. This could resemble an important phase during monocyte
to macrophage differentiation, where the accumulation of further
lipids additional to cholesterol is crucial for the cell [45]. An
inverse situation is seen in our cell density experiments, where the
increase in ASM-1 mRNA expression is accompanied by an
increased cellular ASM activity level. Here, none of the
modulating effects of new ASM isoforms are observed, as their
mRNA expression remains nearly constant. These data stress the
fact that sphingolipid metabolism is significantly influenced by cell
confluence levels [25]. For sphingolipid research using cell culture
models it is of highest importance to consider these influencing
factors. It is not resolved, however, if these physiological effects are
mediated on message or protein level because the detection of
endogenous ASM and its isoforms in Western blot analyses is
currently difficult. But taking together, dominant-negative effects
in sphingomyelin hydrolysis could comprise important regulative
processes in physiological settings.
In conclusion, our study identified three novel human
alternatively spliced ASM transcripts: ASM-5, ASM-6 and
ASM-7. These transcripts show differential expression patterns
in the blood cells of healthy individuals and code for enzymes that
are catalytically inactive in vitro. We were able to show for the first
time that inactive ASM variants can have functional consequences
for cellular processes. We would like to suggest that the alternative
splicing of ASM could be of great importance to the rebalancing of
cellular ASM activity after exposure to stress stimuli. Further
studies are being undertaken to elucidate the role of alternative
splicing in neuro-psychiatric diseases linked to ASM.
Materials and Methods
Ethics Statement
The collection of blood samples was approved by the Ethics
Committee of Friedrich-Alexander-University of Erlangen-Nur-
emberg and conducted in concordance with the Declaration of
Helsinki. Written informed consent was obtained from all
participants.
Identification and Cloning of ASM Transcripts
Total RNA from peripheral blood mononuclear cells (PBMCs)
obtained by Ficoll density gradient centrifugation (Biocoll
Separation Solution, Biochrom, Berlin, Germany) of the blood
from four healthy volunteers and from the human neuroglioma
cell line (H4) was isolated using QIAzol lysis reagent (Qiagen,
Hilden, Germany) in accordance with the manufacturer’s
recommendations. The concentration of RNA was determined
photometrically using a Nanodrop spectrophotometer (Peqlab,
Erlangen, Germany), and RNA integrity was assessed by
nondenaturing agarose gel electrophoresis and capillary gel
electrophoresis (Experion, Bio-Rad, Munich, Germany). cDNA
was synthesised using the VILO cDNA reaction kit (Invitrogen,
Darmstadt, Germany) in a reaction volume of 20 ml with 1 mgo f
total RNA as a template. Full-length ASM transcripts were
amplified by polymerase chain reaction (PCR) in a total reaction
volume of 50 ml with 1 ml of undiluted cDNA, 1 U KAPA HiFi
DNA polymerase in GC-buffer, 1.7 mM MgCl2, 0.3 mM dNTPs
(Peqlab, Erlangen, Germany) and 0.24 mM oligonucleotides
(Operon, Ebersberg, Germany). Primer sequences were based on
the reference sequence of ASM-1. For the PCR, primers carrying
BspE1 and BglII restriction sites for subsequent cloning were
designed to anneal to regions flanking the initiation and stop
codons of ASM-1 (Table 2). Cycle parameters were as follows: an
initial denaturation step at 95uC for 2 min, 35 cycles at 98uC for
Figure 4. New ASM splice variants act in a dominant-negative
manner. A. Modulation of ceramide:sphingomyelin ratios. The
ratio of ceramide levels to sphingomyelin levels significantly increased
after ASM-1 overexpression (p,0.01). In contrast, the ratio significantly
decreased upon overexpression of ASM-5, -6 and -7 (p,0.01 for ASM-6;
p,0.05 for ASM-5 and -7). Lysates were subjected to MALDI-TOF MS for
sphingolipid analysis 24 h after transfection of H4 cells. The data
indicate mean values of n=3 independent experiments; error bars
indicate SD. Statistical significance was calculated with respect to the
control using the t-test (*p,0.05, **p,0.01). B. Co-expression of
ASM-FLAG constructs in HeLa cells. ASM-1 and ASM-5 produced
proteins that corresponded to their predicted sizes independent of
single- or co-transfection. For control reasons lysates derived from two
independent co-transfections were used. Lysates were analysed by
Western blotting 72 h after transfection. ASM-FLAG variants were
detected using an anti-FLAG antibody. The cloning vector served as a
negative control; GAPDH was used as a loading control. M indicates the
size marker. C. ASM-5 exerts a dominant-negative effect on
ASM-1. ASM-1 overexpression generated high ASM activity relative to
a vector control (p,0.001). Co-expression of ASM-1 and ASM-5 at a
ratio of 1:1 led to a significant reduction in ASM activity relative to
conditions where ASM-1 was expressed alone (p,0.01). ASM activity
levels of this co-expression were still above a vector control (p,0.001).
HeLa cells were transfected with 15 mg of ASM-FLAG constructs and
cultured for 48 h. After 24 h of serum-starvation lysates were subjected
to an in vitro enzyme activity assay. The results are presented as the fold
increase in ASM activity relative to a negative control. The displayed
data represent mean values of n=6 independent experiments; error
bars denote SD. Statistical significance was calculated using one-way
ANOVA including a Bonferroni post-hoc test (**p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0035467.g004
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at 68uC for 5 min. In a second approach, RT-PCR was performed
on brain tissue cDNA (Multiple Tissue cDNA, Clontech,
Mountain View, CA) using BioMix white (Bioline, Randolph,
MA) in a total volume of 25 ml, including 3 ml cDNA and 10 pmol
oligonucleotides (fw 59-ccttcattgagggcaaccac-39; rev 59-
ggtatgtttgcctgggtcag-39). Cycle parameters were as follows: initial
denaturation at 94uC for 5 min, 30 cycles at 94uC for 30 sec, 58uC
for 30 sec, 72uC for 1 min, and a final step at 72uC for 10 min.
PCR products were purified using the QIAquick PCR
purification kit (Qiagen, Hilden, Germany) and cloned for analysis
using the StrataClone Blunt PCR cloning kit (Agilent, Waldbronn,
Germany). Amplified products were analysed by sequencing and
compared to the reference sequence of ASM-1.
Quantification of ASM Splicing Events
PCR amplification and capillary electrophoresis with
laser-induced fluorescence analysis. Total RNA from
human lymphoblastoid cell lines was isolated over three
consecutive days using the RNeasy Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s protocol. Human
lymphoblastoid cell lines were Epstein-Barr virus (EBV)-
transformed lymphoblastoid cells cultured in RPMI 1640
medium supplemented with 15% FCS and 2 mM L-glutamine
(Gibco, Eggenstein, Germany) at 37uC, 5% CO2 and 95%
humidity. The human cell lines GM10847, GM12760, GM12864,
GM12870, GM12871, GM15215, GM15324, GM15386,
GM18502, GM18552, GM18858, GM18972, GM19140, and
GM19204 were obtained from the Coriell Cell Repository
(Camden, NJ) and C0766 from the European Collection of Cell
Cultures (Salisbury, UK). cDNA synthesis was performed with the
Sprint RT Complete-Random Hexamer first-strand cDNA
synthesis kit (Clontech-Takara Bio Europe, Saint-Germain-en-
Laye, France) according to the manufacturer’s protocol. 5 mgo f
total RNA were used for reverse transcription. Total RNA from
the blood of healthy volunteers was collected using the PAX
system (Qiagen, Hilden, Germany). A half mg of RNA was used in
a2 0ml reverse transcription reaction (using components of the
VILO cDNA reaction kit (Invitrogen, Darmstadt, Germany)) to
synthesise cDNA.
RT-PCR was performed on the cDNA of human lymphoblas-
toid cells, human blood cells and human tissue (Multiple Tissue
cDNA Panels I and II, Clontech, Mountain View, CA) with
Figure 5. Physiological cell models confirm the dominant-
negative effect of new ASM splice variants. A. PMA induces
mRNA expression of ASM isoforms in THP-1 cells. Upon PMA
treatment, ASM-1 mRNA expression was time-dependently induced.
Expression levels of ASM-5 to -7 rose disproportionately strong. THP-1
cells were treated with 160 nM PMA. After 24, 36 and 48 h, quantitative
RT-PCR analyses were conducted. All ASM RT-qPCR values were
measured in duplicates, normalised against values from the non-
regulated reference gene HPRT and included primer efficiency
calculations. DMSO served as a negative control. The displayed data
represent mean values of triplicates, error bars denote SD. The results
were replicated three times. B. ASM activity levels remain constant
upon PMA treatment of THP-1 cells. Upon 24, 36 and 48 h of PMA
treatment (160 nM), cell lysates were subjected to an in vitro enzyme
activity assay. DMSO served as a negative control. The displayed data
represent mean values of triplicates, error bars denote SD. Results were
replicated three times. C. High density of H4 cells induces mRNA
expression of full-length ASM-1. Depending on increasing cell
density, ASM-1 mRNA expression was significantly induced (p,0.001),
in contrast to the expression of splice variants ASM-5, -6 and –7. H4 cells
were grown to varying levels of confluence. After 72 h, quantitative RT-
PCR analyses were conducted. All ASM RT-qPCR values were measured
in duplicates and normalised against values from the non-regulated
reference gene HPRT. The displayed data represent the mean values of
three independent experiments, error bars denote SD. Statistical
significance was calculated using one-way ANOVA including a post-
hoc test for linear trend (*** p,0.001). D. High density of H4 cells
increases ASM activity. The increase in cellular density significantly
increased cellular ASM activity (p,0.001). H4 cells were grown to
varying levels of confluence. Upon 72 h cell lysates were subjected to
an in vitro enzyme activity assay. The displayed data represent the mean
values of three independent experiments, error bars denote SD.
Statistical significance was calculated using one-way ANOVA including
a post-hoc test for linear trend (*** p,0.001).
doi:10.1371/journal.pone.0035467.g005
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including 3 ml of cDNA and 10 pmol of oligonucleotides (Table 3).
Cycle parameters were as follows: initial denaturation at 94uC for
5 min, 30 cycles at 94uC for 30 sec, 58uC for 30 sec, 72uC for
1 min, and a final step at 72uC for 10 min. Capillary
electrophoresis with laser-induced fluorescence analysis was
conducted as described in [46].
Quantitative RT-PCR of ASM splice variants. Total RNA
using the High Pure RNA Isolation Kit (Roche, Mannheim,
Germany) was collected from human acute monocytic leukaemia
THP-1 cells provided by M. Lehner [47], which were cultured in
RPMI 1640 medium supplemented with 10% (v/v) FCS and
2 mM L-glutamine and differentiated using 160 nM phorbol 12-
myristate 13-acetate (PMA; Sigma-Aldrich, Munich, Germany).
Total RNA from human neuroglioma H4 cells (Promochem,
Wesel, Germany), cultured in DMEM medium supplemented with
10% (v/v) FCS and 4 mM L-glutamine, was collected using
QIAzol lysis reagent (Qiagen, Hilden, Germany) in accordance
with the manufacturer’s recommendations. The concentration of
RNA was determined photometrically using a Nanodrop
spectrophotometer (Peqlab, Erlangen, Germany) and RNA
integrity was assessed by nondenaturing agarose gel
electrophoresis and capillary gel electrophoresis (Experion, Bio-
Rad, Munich, Germany). A half mg of RNA was used in a 20 ml
reverse transcription reaction (using components of the VILO
cDNA reaction kit (Invitrogen, Darmstadt, Germany)) to
synthesise cDNA.
RT-qPCR analyses were performed in a reaction volume of
10 ml with the SYBR green I master mix (Roche, Mannheim,
Germany), 2.5 ml of diluted cDNA and HPLC-purified oligonu-
cleotides at a final concentration of 1 mM each (Operon,
Ebersberg, Germany) (Table 4) in white multiwell plates (Roche,
Mannheim, Germany). Oligonucleotides were tested for target-
specificity (Figure S3). Cycle parameters were as follows: initial
denaturation at 95uC for 5 min, 40 cycles at 95uC for 10 sec, ASM
variant-specific primer annealing temperatures for 20 sec and
72uC for 20 sec. Expression levels of ASM transcripts were
normalised against RT-qPCR values for the invariant reference
gene HPRT (NM_000194.2). Data were analysed with the
LightCyclerH 480 software (Roche, Mannheim, Germany), which
provides algorithms for an advanced relative quantification
method that includes calibrator normalising and the calculation
of primer efficiency for each target. Melting curves were
monitored and amplification products were verified by agarose
gel electrophoresis (1%) and subsequent nucleotide sequencing.
The RT-qPCR analyses were performed in accordance with
MIQE guidelines [48]. For further details on the analyses, see
Table S2.
Overexpression Studies on ASM Isoforms
Construction of expression plasmids. Open reading
frames were amplified from the plasmids into which the initial
PCR products were cloned using a single forward primer and
reverse primers specific for different truncated variants (Table 2).
Amplimers were digested with the BspE1 and BglII restriction
endonucleases and inserted between XmaI and HindIII sites in the
FLAG-N2 expression vector to create an in-frame C-terminal
fusion of various ASM gene products with the 16 amino acid
FLAG-tag. Each inserted sequence was verified by sequence
analysis.
Cell Culture. H4, HeLa and HEK293 cells (Promochem,
Wesel, Germany) were cultured in DMEM medium supplemented
with 10% (v/v) FCS and 4 mM (for H4 cells) or 2 mM L-
glutamine (for HeLa and HEK293 cells). Cells were maintained at
37uC in a humidified atmosphere with 8.5% CO2 and were
monitored for potential mycoplasma infection using the
MycoAlert Mycoplasma Detection Kit (Lonza, Cologne,
Germany). All reagents used for cell culture were purchased
from Biochrom (Berlin, Germany).
For transfection purposes, cells were grown to 60% confluence
in 6-well plates with 2 ml of culture medium. Transfections were
performed by the calcium phosphate precipitation procedure.
7.5 mg of plasmid DNA were mixed with 2x N,N-Bis(2-
hydroxyethyl)-2-aminoethanesulfonic acid (BES) buffer [50 mM
BES, 280 mM NaCl, 1.5 mM Na2HPO4, pH 6.98 (for H4 and
HeLa cells) and pH 7.01 (for HEK293 cells); all chemicals were
obtained from Sigma-Aldrich (Munich, Germany)] containing
10 ml 2.5 M calcium chloride, incubated for 20 min at room
temperature, and added to cells. The culture medium was changed
17 h after transfection. Transfection efficiency was approximately
70–80%, as determined by the number of GFP-positive cells after
a parallel control transfection with the expression vector pmaxFP-
green-C (Lonza, Cologne, Germany).
Table 3. Oligonucleotides used for RT-PCR and subsequent capillary electrophoresis.
ASM exons Forward sequence 5’ -. 3’ Reverse sequence 5’ -. 3’ Annealing
Exon 2 to 4 FAM-tcctggggccagtgccag cagctcttcagacagtgcc 58uC
Exon 4 to 6 FAM-caggatgtaggtctcatggtc gctggagctggaattattacc 58uC
Exon 2 to 6 FAM-ccttcattgagggcaaccac ggtatgtttgcctgggtcag 58uC
doi:10.1371/journal.pone.0035467.t003
Table 2. Oligonucleotides used for cloning of ASM transcripts.
ASM transcript Forward sequence 5’ -. 3’ Reverse sequence 5’ -. 3’ Annealing
ASM-1; ASM-5 tccctccggaatgccccgctacggagc gcgagatctgcaaaacagtggccttgg 65uC
ASM-6 tccctccggaatgccccgctacggagc ggaagatctacgggaacaaaaattcatatgaagagagagg 65uC
ASM-7 tccctccggaatgccccgctacggagc ggaagatctcgggaacaaaaattcatattgagagagatg 65uC
doi:10.1371/journal.pone.0035467.t002
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buffer [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40,
0.5% sodium deoxycholate, 0.1% SDS (Sigma-Aldrich, Munich,
Germany) into which were dissolved complete protease inhibitor
tablets from Roche (Mannheim, Germany)]. Cell debris was
removed by centrifugation at 10,000 g for 15 min at 4uC. The
protein concentration of the cell extracts was determined using the
BCA assay (Bio-Rad, Munich, Germany). Sample aliquots were
denatured in Laemmli buffer for 5 min [49]. Total protein (10 mg)
was separated by 10% SDS gel electrophoresis and transferred to a
PVDF-membrane (Millipore, Schwalbach/Ts, Germany). Blots
were incubated in 2.5% milk powder (Roth, Karlsruhe, Germany)
and 0.1% Tween 20 (Sigma-Aldrich, Munich, Germany) in PBS at
4uC overnight. Subsequently, the blots were incubated for 4 h at
room temperature with a primary mouse monoclonal anti-FLAG-
antibody (1:1000; Sigma-Aldrich, Munich, Germany), for 1 h with
a primary mouse glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) antibody (1:200,000); Millipore, Schwalbach/Ts,
Germany), and then for 1 h with a secondary goat anti-mouse
IgG antibody coupled to horseradish peroxidase (1:10,000;
Dianova, Hamburg, Germany). All antibodies were diluted in
0.5% milk powder solution (Roth, Karlsruhe, Germany) and 0.1%
Tween 20 in PBS (Sigma-Aldrich, Munich, Germany). Detection
was performed using the enhanced chemiluminescence (ECL)
Western blotting detection system (Amersham, Munich, Germany)
and visualised on a high-sensitivity camera device (FluorSMax,
Bio-Rad, Munich, Germany).
In vitro determination of ASM activity. Enzymatic ASM
activity in the cell extracts was determined as previously described
[24]. Quantitative analysis of ASM activity was performed with
10 mg of total cellular protein extract diluted in 250 ml of sodium
acetate buffer [250 mM sodium acetate pH 5.0 (Merck,
Darmstadt, Germany), 0.1% NP-40 (Sigma-Aldrich, Munich,
Germany), 1.3 mM EDTA (Sigma-Aldrich, Munich, Germany)
and 1 tablet of complete mini protease inhibitor mix per 10 ml of
buffer (Roche, Mannheim, Germany)]. 440 pmol
14C-
radiolabelled C12-sphingomyelin (Perkin-Elmer, MA, USA)
suspended in 30 ml of enzyme buffer [250 mM sodium acetate
pH 5.0 (Merck, Darmstadt, Germany), 0.1% NP-40 (Sigma-
Aldrich, Munich, Germany), 1.3 mM EDTA (Sigma-Aldrich,
Munich, Germany)] was added to the protein extract. The
enzymatic reaction was incubated at 37uC for 20 min and then
stopped with the addition of 800 ml of chloroform/methanol (2:1,
v/v). The two phases were separated by centrifugation. The
radioactivity of the
14C-labelled product, phosphorylcholine, in the
aqueous phase was determined by liquid scintillation counting and
was used to calculate ASM activity.
ASM activity was also determined using the fluorescent
substrate BODIPY-C12-sphingomyelin (Invitrogen, Darmstadt,
Germany). In this assay, 2 ml of the cell extracts (typically
corresponding to 0.5-2 mg of protein) were added to 116 pmol
of fluorescent substrate in sodium acetate buffer [200 mM sodium
acetate pH 5.0, 500 mM NaCl and 0.2% NP-40] in a total volume
of 100 ml. After incubation for 0.5 to 4 h at 37uC, the fluorescent
product ceramide and the uncleaved substrate were extracted by
the addition of 250 ml chloroform/methanol (2:1, v/v). Following
vortexing and centrifugation, the organic phase was concentrated
in a SpeedVac vacuum concentrator and spotted on silica gel 60
plates (Macherey-Nagel, Du ¨ren, Germany). Ceramide and
sphingomyelin were separated by thin layer chromatography
using chloroform/methanol (4:1, v/v) as a solvent and quantified
on a Typhoon Trio scanner (GE Healthcare, 488 nm excitation
and 520 nm emission wavelengths, 280 V, 100 mm resolution)
with QuantityOne software (Bio-Rad, Munich, Germany). Mea-
surements were performed in triplicates. The enzymatic activity of
ASM was calculated as the rate of hydrolysis of sphingomyelin to
ceramide per hour and per mg of protein in the cell lysate sample
(pmol/h/mg).
MALDI-TOF MS analysis of cellular ceramide and
sphingomyelin levels. Transfected H4 cells were lysed in
100 ml of lysis buffer [20 mM Tris-HCl pH 7.4, 100 mM butylated
hydroxytoluene (spectrophotometric grade, Sigma-Aldrich,
Munich, Germany)], immediately frozen in liquid nitrogen and
stored at –80uC. After thawing, the cell samples were homogenised
and sonicated. The lipid content was subjected to classical
chloroform/methanol extraction [50], transferred to a clean
tube, dried and resuspended (2%, w/v) in chloroform. Samples
were mixed with a matrix consisting of 0.5 M 2.5-
dihydroxybenzoic acid in methanol and 0.1% trifluoroacetic
acid (spectrophotometric grade, Sigma-Aldrich, Munich,
Germany) [51]. Aliquots were spotted on a steel target and
subjected to mass spectrometric analysis. Mass spectra were
obtained using an Autoflex MALDI-TOF MS (Bruker Daltonics,
Bremen, Germany) equipped with a nitrogen laser (l =337 nm).
Mass spectra were acquired in reflectron and positive ion modes.
Each spectrum consists of an average of 100 laser shots.
Mass-to-charge ratio (m/z) values were compared to the lipid
database LIPID MAPS (http://www.lipidmaps.org), according to
which the corresponding ceramide and sphingomyelin species
were defined for semi-quantitative analysis [52] (Table S1). The




+, were determined and summarised. The ratio of ceramide
to sphingomyelin intensities was calculated for each individual
spectrum and a mean value was determined by three independent
experiments.
Bioinformatic and Statistical Analyses
In silico analyses of ASM orthologous transcripts were performed
using tools in the NCBI database. Alignments were generated with
the ClustalW alignment software of the European Bioinformatics
Institute (www. ebi.ac.uk/clustalw). Protein molecular weights
were calculated with the aid of the molecular weight calculator at
Table 4. Oligonucleotides used for RT-qPCR analyses.
Transcript Forward sequence 5’ -. 3’ Reverse sequence 5’ -. 3’ Amplicon (bp) Annealing
ASM-1 cctcagaattggggggttctatgc cacacggtaaccaggattaagg 412 62uC
ASM-5 tgcagacccactgtgctgc aagttctcacgggaactgagggtgcgcagg 440 68uC
ASM-6 gctgcctgccgaagccctgc gcaaggatgtggggctgacagg 440 68uC
ASM-7 tgcagacccactgtgctgc accccccaattctttcttttccc 474 68uC
HPRT tccgcctcctcctctgctc gaataaacaccctttccaaatcctca 185 62/68uC
doi:10.1371/journal.pone.0035467.t004
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lysed for statistical significance with IBM SPSS Statistics 19
software (SPSS Inc., Chicago, IL, USA).
Supporting Information
Figure S1 The coding sequences of full-length ASM-1
and alternatively spliced transcripts ASM-5, -6 and -7
differ at specific locations. The ASM-5 transcript lacks the
first 69 bp of exon 3 and, consequently, has a shorter coding
length (relative to ASM-1) of 1818 bp. The ASM-6 transcript is
characterised by a 20 bp intronic insertion derived from the end of
intron 5. It has a transcript length of 1907 bp. ASM-7 contains a
40 bp intronic sequence derived from the beginning of exon 2,
which results in a 1921 bp transcript. All of the transcripts are
clearly the result of alternative splicing events because they display
sequence identity with the full-length ASM along their lengths,
except at the locations described above. Grey portions indicate
those sequences that differ from the ASM-1 coding sequence. Stop
codons are displayed in bold. The alignment was generated using
ClustalW.
(DOC)
Figure S2 The putative protein sequence of each novel
isoform displays specific features. In comparison with the
full-length ASM-1 protein, which consists of 631 amino acids and
has a theoretical molecular weight of 70 kDa, ASM-5 is 606 amino
acids long and has a theoretical molecular weight of 67 kDa. It
carries a disrupted catalytic domain due to the loss of 23 amino
acids. ASM-6 constitutes a 506 amino acid protein with a
theoretical molecular weight of 56 kDa. It has an intact catalytic
domain but lacks the C-terminal domain. Instead, it carries a
unique C-terminal peptide composed of 13 amino acids,
VSPTSLQVTVCTK. ASM-7 consists of 398 amino acids and
has a theoretical molecular weight of 45 kDa. Like ASM-6, it is a
smaller protein because of a truncated open reading frame. ASM-
7 has a partial catalytic domain and entirely lacks the C-terminal
domain of ASM-1. At its C-terminus, it carries a unique peptide of
38 amino acids (YLSSVETQEGKRKNWGVLCSF-
PIPRSPPHLSQYEFLFP). Specific protein sequences are indicat-
ed in grey. The protein domains are coloured differently: yellow,
signal peptide (aa 1–48); light blue, saposin-B-domain (aa 91–167);
purple, proline-rich-domain (aa 168–200); red, catalytic domain
(aa 201–463); green, C-terminal domain (aa 464–631). Mannose-
6-phosphate sites (Asn 88, 177, 337, 397, 505, 522) are indicated
in light green. The alignment was performed using ClustalW.
(DOC)
Figure S3 Target-specificity of primer pairs designed
for amplification of ASM transcripts. Amplification of
ASM-1 and each novel ASM transcript using the respective primer
pair resulted in a specific PCR-product of the expected size
separated on a 1% agarose gel. Cloned transcripts were used as
templates; water served as a negative control (C). Amplimers were
verified by sequence analysis.
(TIF)
Table S1 MALDI-TOF MS detection of sphingomyelin
and ceramide species for semi-quantitative analysis.
(DOC)
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